Key takeaway
Across 16 randomized trials (N=910), wearable digital interventions in adults with insomnia were linked to a 4.52-minute shorter objective sleep-onset latency (95% CI -8.38 to -0.67) and 2.00% higher subjective sleep efficiency, but no improvement in the insomnia severity index (ISI). The prediction intervals for some outcomes include no effect, so the authors call the findings preliminary.
Study design
Trial meta-analysis
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
Many people use wearables to monitor and improve sleep, but earlier meta-analyses mixed digital therapies together and rarely separated stand-alone wearables or objective from subjective measures. The authors asked whether stand-alone wearable interventions improve sleep in adults with insomnia, and whether wearing position, duration or control type explains differences between trials.
Who and how
Systematic review and meta-analysis following PRISMA 2020 and PRISMA-S. Five databases and trial registries were searched from inception to May 18, 2026. Included were randomized controlled trials of wearable digital interventions in adults with insomnia compared with sham, waitlist, usual care or active control, lasting at least 1 week. Two reviewers independently screened, extracted data and assessed risk of bias. Estimates used a restricted maximum likelihood random-effects model with the Hartung-Knapp-Sidik-Jonkman correction, with I² for heterogeneity, 95% prediction intervals (PIs) and GRADE for certainty. Meta-regression examined device location, duration and control type.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 116 RCTs (N=910) were included. Objective sleep-onset latency fell by a mean difference (MD) of 4.52 minutes (95% CI -8.38 to -0.67), but the prediction interval, -9.52 to 0.47 minutes, includes no effect.
- 2Subjective sleep efficiency improved by 2.00% (95% CI 1.90%-2.11%, PI 1.85%-2.15%). Subjective total sleep time rose by 19.11 minutes (95% CI 2.98-35.24), with a PI of -16.20 to 54.43 minutes that includes no effect.
- 3Overall insomnia severity (ISI) did not improve. Control type, intervention duration and device location did not explain heterogeneity in ISI (R²=0), sensitivity analysis supported the ISI estimates, and the Egger test showed no small-study effects (P =.07).
- 4Certainty of evidence ranged from moderate to high.
Limits & uncertainty
- 1Only 16 trials with 910 participants in total, spread over several outcomes, so each pooled estimate rests on a few studies.
- 2Prediction intervals for sleep-onset latency and total sleep time include zero, so a new trial might find no benefit; the authors cite wide PIs and substantial heterogeneity.
- 3The gains are small on average (4.52 minutes for sleep onset), and it is unclear whether they matter to patients; ISI, the overall severity score, did not improve.
- 4The abstract does not say which devices or intervention types were pooled, and it pools wearables placed in different positions. This reading uses the abstract only.
What to take from it
Wearable-based tools may give a small, selective improvement in sleep onset, sleep efficiency and total sleep time, but not in how severe insomnia feels overall. The authors say wearables are possible low-cost add-ons, not substitutes for first-line cognitive behavioral therapy for insomnia. Persistent insomnia is worth discussing with a clinician.
Reading your own data
Wearables estimate sleep onset and sleep time with error, so small nightly differences are noise. Compare multi-week averages on the same device, and keep a short note of how rested you feel, since the insomnia severity score here did not change.
How to read this evidence
Pooling trials can improve precision, but compare populations, controls, bias and uncertainty. Network rankings include indirect evidence and do not identify a universal best treatment.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
Wearable devices are increasingly used for sleep monitoring and as adjunctive treatment. Existing meta-analyses mostly pool composite digital therapies and rarely isolate stand-alone wearables or distinguish between objective and subjective end points. Whether stand-alone wearable interventions improve sleep outcomes in adults with insomnia, and which factors moderate treatment heterogeneity, remains unclear.
Objective
This study aims to evaluate the effectiveness of wearable digital interventions on sleep outcomes in adults with insomnia versus control strategies and explore moderators of effectiveness, including device-wearing position, intervention duration, and control type, using meta-regression.
Methods
This systematic review and meta-analysis was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‑Analyses) 2020 statement and the PRISMA-S (Preferred Reporting Items for Systematic Reviews and Meta‑Analyses Literature Search Extension) guideline. Five electronic databases and clinical trial registries were searched from inception to May 18, 2026. Eligible studies were randomized controlled trials (RCTs) evaluating wearable digital interventions in adults with insomnia compared with sham, waitlist, usual care, or active control conditions and had an intervention duration of at least 1 week. Study screening, data extraction, and risk-of-bias assessment were carried out independently by 2 reviewers. Pooled estimates were calculated using a restricted maximum likelihood random-effects model with the Hartung-Knapp-Sidik-Jonkman correction. Heterogeneity was assessed using the I ² statistic, and 95% prediction intervals (PIs) were calculated for the primary analyses. The certainty of evidence was rated using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.
Results
Sixteen RCTs (N=910) were included. Wearable digital interventions were associated with a significant reduction in objective sleep-onset latency (SOL; mean difference [MD] -4.52, 95% CI -8.38 to -0.67, PI -9.52 to 0.47 min) and a significant improvement in subjective sleep efficiency (SE; MD 2.00%, 95% CI 1.90%-2.11%, PI 1.85%-2.15%). Subjective total sleep time (TST) also showed a significant increase (MD 19.11, 95% CI 2.98-35.24, PI -16.20 to 54.43 minutes). Meta-regression showed that control type, intervention duration, and device location did not explain the heterogeneity of the insomnia severity index (ISI) ( R ^(²)=0). Sensitivity analysis confirmed the robustness of pooled ISI estimates, and an Egger test indicated no small-study effects ( P =.07). Certainty of evidence ranged from moderate to high.
Conclusions
Wearable digital interventions provide selective benefits for objective SOL, subjective SE, and subjective TST in adults with insomnia, with no improvement in overall ISI. Despite statistically significant effects on several sleep parameters, wide PIs, substantial heterogeneity, and limited study numbers indicate preliminary, nonconclusive findings. Wearables should be viewed as affordable adjunctive tools requiring further validation, not substitutes for first-line cognitive behavioral therapy for insomnia. Large-scale, long-term RCTs with standardized protocols and patient-level external validation are required to consolidate the evidence base.
Sources & attribution
Effectiveness of Wearable Digital Therapeutics in Improving Sleep Outcomes Among Individuals With Insomnia: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zhu W, Chen M, Guo Y, Zhang B, Luo C.
Journal of medical Internet research · 2026-09-11
DOI: 10.2196/93496 ↗PubMed · 42727109 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Activity–stroke and heart attack curves differ by accelerometer processing method
Among 90,237 UK Biobank adults free of cardiovascular disease at baseline, followed until December 2022 for 1,298 strokes and 2,031 myocardial infarctions, the shape of the link between moderate-vigorous physical activity (MVPA) and each outcome depended on how the accelerometer data were processed. For stroke, hazard fell in a straight line only with the machine-learning metric; for myocardial infarction, two metrics gave a curved decline and activity counts a straight one. The abstract gives no hazard ratios, so it shows that methods disagree, not which one is right, and the findings are observational associations.
Preventive Medicine
Smartwatch data as forensic evidence: heart rate is best validated, the rest uneven
A systematic review and meta-analysis of studies on smartwatches from four major brands, framed around digital forensics, found that heart rate was both the most studied and the most accurate measure. Step count, distance, energy expenditure, activity classification and sleep were less consistently validated, and results varied by brand, protocol and reporting. The abstract gives no pooled numbers, and most studies were run in healthy people in laboratories, so it cannot say how a particular watch performs for a particular person in daily life.
Forensic Science International
Activity trackers: about 1,800 more steps a day, but small effects on other outcomes
An umbrella review of 39 systematic reviews and meta-analyses, covering 163,992 participants, found that activity trackers were associated with more physical activity (SMD 0.3–0.6), equating to about 1,800 extra steps and 40 minutes more walking per day, and with a bodyweight reduction of about 1 kg. Effects on blood pressure, cholesterol, glycosylated haemoglobin, quality of life and pain were typically small and often non-significant. The abstract does not say what else came with the trackers in these programs or how much the reviews overlap, so the gains cannot be credited to the device alone.
The Lancet Digital Health
Seven sleep trackers: good at spotting sleep, weak on wake and sleep stages
In a sleep laboratory, 34 healthy young adults wore a subset of seven consumer sleep trackers for three nights. Against polysomnography every device detected sleep very well (sensitivity 0.93 or higher) but caught wake poorly (specificity 0.18–0.54), and five of the seven matched or beat research actigraphy (specificity 0.39). Sleep-stage estimates were inconsistent, and the participants were healthy adults aged 18 to 35 in a fixed 8-hour bed window, with each device tested in only 11 to 20 of them, so the results say little about people with sleep problems.
Sleep

